At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Vadadustat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
In Brief
A Phase 2 clinical trial evaluating Vadadustat and Placebo for Anemia and Non-dialysis Dependent Chronic Kidney Disease. Completed, enrolled 51 participants across 18 sites.
Detailed Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of orally administered vadadustat in Japanese participants with anemia secondary to Non-dialysis Dependent Chronic Kidney Disease (NDD-CKD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedFeb 2017
Primary CompletionJul 2017
Study CompletionAug 2017
TodayJul 2026
First PostedFeb 15, 2017
Enrollment StartOct 1, 2016
Primary CompletionJul 4, 2017
Study CompletionAug 28, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.4 years ago
Interventions
Vadadustatdrug
Placebodrug